POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. et al

Track this case

Case overview

Case Number:

3:15-cv-07658

Court:

New Jersey

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Michael A. Shipp

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 09, 2018

    Options Broker Must Stay In TIAA-Led Class In Valeant Suit

    An options brokerage can't break away from a consolidated securities class action against Valeant Pharmaceuticals, a New Jersey federal judge ruled after finding that it was too early to tell whether the firm's interests would diverge from the larger pool of equity investors led by TIAA.

  2. August 08, 2018

    TIAA Says It Should Be Only Lead Plaintiff In Valeant Suit

    Lead plaintiff TIAA urged a New Jersey federal judge on Tuesday to strike a brokerage firm's bid to lead a subclass of Valeant options investors in a multibillion-dollar consolidated securities class action against the pharma giant, warning that the firm's request risks splintering the suit and driving up costs for all involved.

  3. May 01, 2017

    Valeant Securities Fraud Case Lives, Could Lose Debt Claims

    A New Jersey federal judge allowed a multibillion-dollar securities class action against Valeant Pharmaceuticals International Inc. and its top officials to move forward on Friday, although claims related to $15 billion in corporate debt that was issued under allegedly fraudulent pretenses may be cut.

  4. December 15, 2016

    Valeant Offering Needn't Meet Public Standards, SIFMA Says

    The Securities Industry and Financial Markets Association urged a New Jersey federal court Wednesday to reject an attempt to hold Valeant Pharmaceuticals International Inc.'s private securities sale up to public sale standards.

  5. September 14, 2016

    Valeant Says Investors' Suit Is Based On Hindsight

    A proposed class of investors claiming Valeant Pharmaceuticals International Inc. fraudulently hid questionable relationships with specialty pharmacies and is liable for a massive stock drop relied on hindsight following a "perfect storm" of negative publicity and hasn't actually shown proof of any fraud, the company said Tuesday in New Jersey federal court.

  6. May 31, 2016

    Robbins Geller Will Lead Valeant Securities Fraud Suit

    A New Jersey federal judge on Tuesday appointed a teacher's retirement fund as lead plaintiff and Robbins Geller Rudman & Dowd LLP as lead counsel in consolidated related class actions alleging that Valeant Pharmaceuticals International Inc. fraudulently inflated its stock price, causing the fund to suffer more than $90 million in losses.

  7. December 22, 2015

    Robbins Geller Looks To Lead Valeant Securities Fraud Suit

    A teacher's retirement fund that alleges Valeant Pharmaceuticals fraudulently inflated its stock price, causing the fund to lose more than $90 million, asked a New Jersey federal court Monday to consolidate four related putative class actions and name it lead plaintiff with Robbins Geller Rudman & Dowd LLP as lead counsel.

  8. October 23, 2015

    Valeant Hit With Investor Suit Over Pharmacy Ties

    Valeant Pharmaceuticals International Inc. fraudulently concealed questionable relationships with specialty pharmacies and is liable for steep losses that shareholders suffered after the relationships came to light, according to a proposed securities class action filed Thursday in New Jersey federal court.